Tag: arteriovenous fistula
Xeltis receives IDE approval from US FDA for haemodialysis vascular access...
Xeltis has announced that it has gained approval from the US Food and Drug Administration (FDA) for an investigational device exemption (IDE) submission to...
Laminate Medical announces first implantation of VasQ AVF device
Laminate Medical has announced the first implantation of their VasQ device in the USA, performed by Ari Kramer (Spartanburg Regional Hospital, Spartanburg, USA). The...
Aperto® DCB: A breakthrough in prolonging dialysis access survival
This advertorial is sponsored by Cardionovum.
Cardionovum’s CE-marked Aperto drug-coated balloon (DCB) is, according to expert opinion and a growing evidence base, spearheading a revolution...
Laminate Medical announces FDA clearance for VasQ AVF creation device
Laminate Medical Technologies has announced their flagship device, the VasQ External Vascular Support, has been cleared by the US Food and Drug Administration (FDA)...
Alucent Biomedical granted US FDA approval for clinical study
Alucent Biomedical has announced that the US Food and Drug Administration (FDA) granted an investigational device exemption (IDE) for a US clinical study of...
Pathfinder Medical and Imperial College London awarded Innovate UK Smart grant...
Pathfinder Medical has been awarded a Smart grant for a £1.1 million (US$1.4 million) project by Innovate UK, the UK's innovation agency. A press...
The Aperto® drug-coated balloon: A “first-line” treatment for arteriovenous fistula lesions
This advertorial is sponsored by Cardionovum®.
In 2023, there are a number of different options available for treating the vascular access complications of thrombosis and...
Arteriovenous graft use linked to venous thromboembolism risk in haemodialysis patients
In an observational cohort study of Medicare beneficiaries receiving haemodialysis, the use of an arteriovenous graft (AVG) compared with an arteriovenous fistula (AVF) was...
Intraoperative vascular mapping during haemodialysis access “should be incorporated into routine...
Intraoperative ultrasonographic venous mapping is a useful tool to evaluate vessel suitability for arteriovenous fistula (AVF) creation, Yana Etkin (Zucker School of Medicine at...
VentureMed completes enrolment of Flex Vessel Prep system randomised controlled trial...
VentureMed Group recently announced that it has completed enrolment of a randomised controlled trial (RCT) titled 'Flex Vessel Prep prior to PTA for the...
New sirolimus data provide encouragement despite “potentially disappointing” efficacy results
The results of a small-scale pilot study from Asia have indicated “potentially disappointing” results with a novel drug-eluting balloon in treating dysfunctional arteriovenous access...
Humacyte announces publication of positive long-term follow-up data from phase 2...
Humacyte today announced that five-year data from a phase 2 clinical trial of patients receiving the investigational Human Acellular Vessel (HAV) for arteriovenous (AV)...
Benefits of percutaneous fistula creation further bolstered by five-year Ellipsys data
The Ellipsys vascular access system (Avenu Medical/Medtronic) can be used to easily and safely create durable percutaneous arteriovenous fistulas (pAVFs) for haemodialysis—with new, long-term...
“Very encouraging” 12-month data from WRAPSODY FIRST study presented at CIRSE...
Twelve-month results from a first-in-human study of the Wrapsody cell-impermeable endoprosthesis (Merit Medical Systems) for the treatment of access circuit stenosis in haemodialysis patients...
Results from first-in-human study of Amplifi vein dilation system presented at...
Preliminary clinical results from a first-in-human study assessing the Amplifi vein dilation system (Artio Medical) were presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October...
Arteriovenous fistulas contribute to higher survival of haemodialysis patients with COVID-19
A new study, published online in The Journal of Vascular Access (JVA), suggests that arteriovenous fistulas (AVFs) contribute to higher survival of haemodialysis patients...
More mixed results for DCBs in AV access maintenance as evidence...
Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with...
Arterial diameter may help to predict AVF aneurysm progression, study suggests
A recent study concludes that arterial diameter may influence arteriovenous fistula (AVF) aneurysm progression and the interval to surgical revision. “Patients with larger arterial...
VasQ device improves AVF creation in haemodialysis patients
VasQ, a high haemocompatibility biosynthetic vascular device from Laminate Medical Technologies, could be protective against the haemodynamic modifications that occur during arteriovenous fistulae (AVF)...
Network meta-analysis finds DCB angioplasty “significantly superior” to plain balloon angioplasty...
A recent network meta-analysis shows that, in failing arteriovenous fistulas (AVFs) with outflow stenosis, drug-coated balloon (DCB) angioplasty is “significantly superior” to plain balloon...
Patient-specific computation model may improve AVF maturation rates
The results of a randomised controlled trial—the Shunt simulation study—show that a new patient-specific computation model accurately calculated postoperative access flow. As flow is...
Six-month IN.PACT AV Access results published, show superiority of DCB angioplasty
Just-published six-month results of the IN.PACT AV Access study show that drug-coated balloon (DCB) angioplasty is superior to standard angioplasty for the treatment of...
Ultrasound-guided PTA is a “valuable tool” to treat vascular access stenosis
Routine ultrasound-guided percutaneous transluminal angioplasty (PTA) is a feasible treatment for native arteriovenous fistula (AVF) dysfunction, according to a recent study by Antonio Granata...
VasQ external support awarded breakthrough device designation by the FDA
The US Food and Drug Administration (FDA) has designated Laminate Medical’s VasQ external support for the creation of arteriovenous fistulas (AVF) in haemodialysis patients...
Enrolment of the VasQ external support US pivotal study now complete
Laminate Medical Technologies has announced the completion of enrolment into the VasQ external support US pivotal study. The study was conducted at 17 sites...
Merit Medical receives FDA breakthrough device designation for WRAPSODY endovascular stent...
Merit Medical Systems recently announced that it has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA) for the Merit...
e-PTFE covered stent demonstrates “significantly better” target lesion primary patency compared...
The results of AVeNEW, the first level one clinical study dedicated solely to the use of a covered stent designed to treat stenosis in...
MagicTouch AVF sirolimus-coated balloon granted breakthrough device designation for use in...
Concept Medical has been granted breakthrough device designation from the US Food and Drug Administration (FDA) for MagicTouch AVF, its sirolimus drug-coated balloon (DCB)...
VasQ External Support demonstrates significant improvement in fistula usability
Laminate Medical Technologies (Laminate) has announced that the American Journal of Kidney Disease has published the first multicentre, randomised controlled study of the VasQ...
First patients enrolled in US pivotal trial of the VasQ device
The first patients have been enrolled in the US FDA pivotal study of VasQ (Laminate Medical Technologies), an implanted blood vessel external support device...
Promising results with novel external pneumatic device for fistula maturation
Renal failure affects millions of patients worldwide, with many renal failure patients progressing to end-stage renal disease, requiring dialysis treatment. Dialysis options include central...
Flow Forward reports Arteriovenous Fistula Eligibility system data
Flow Forward Medical has announced the completion of a preclinical study and a computational fluid dynamics study supporting continued development of the company's Arteriovenous...
VasQ series at Berlin’s Charité University Hospital produces “exceptionally promising results”
As part of the main scientific programme at Dreiländertagung 2016 (4–8 October, Bern Switzerland), Peter Olschewski has reported “exceptionally promising results” from the first...
